Skip to content

Replimune Group REPL Additional Paid-In Capital

Additional Paid-In Capital at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$14.4B+9.2%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$258.59M+6.0%
Immunome logo
ImmunomeIMNM
$1.37B+58.5%
CG Oncology logo
CG OncologyCGON
$1.53B+59.9%
Erasca, Inc. logo
Erasca, Inc.ERAS
$1.47B+22.7%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$2.73B+7.6%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's additional paid-in capital?
Replimune Group (REPL) reported additional paid-in capital of $1.39B in Q4 2025.
How has Replimune Group's additional paid-in capital changed year-over-year?
Replimune Group's additional paid-in capital increased by 3.2% year-over-year, from $1.35B to $1.39B.
What is the long-term trend for Replimune Group's additional paid-in capital?
Over 4 years (2021 to 2025), Replimune Group's additional paid-in capital has grown at a 18.4% compound annual growth rate (CAGR), from $692.24M to $1.36B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.